| Identifiers | |
|---|---|
| |
| PubChem CID | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C26H28F2N4O |
| Molar mass | 450.534 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
FG5865 is from the diphenylbutylpiperazine class of agents. It is a 5-HT1A agonist and a 5-HT2A antagonist.1
It is believed to be an anxiolytic agent with treatment in substance abuse disorders particularly alcoholism.23
There is evidence to suggest that FG5865 is a SNDRI.4
References
References
- Myers RD (1994). "New drugs for the treatment of experimental alcoholism". review. Alcohol. 11 (6). Fayetteville, N.Y.: 439–451. doi:10.1016/0741-8329(94)90064-7. PMID 7865140.
- Hjorth S, Pettersson G (July 1993). "5-HT1A autoreceptor-mediated effects of the amperozide congeners, FG5865 and FG5893, on rat brain 5-hydroxytryptamine neurochemistry in vivo". European Journal of Pharmacology. 238 (2–3): 357–367. doi:10.1016/0014-2999(93)90867-H. PMID 7691622.
- Long, T. (January 1996). "Alcohol intake in high alcohol drinking (HAD) rats is suppressed by FG5865, a novel 5-HT1A agonist/5-HT2 antagonist". Pharmacology Biochemistry and Behavior. 53 (1): 33–40. doi:10.1016/0091-3057(95)00195-6. PMID 8848457.
- Pettersson E (August 1995). "Studies of four novel diphenylbutylpiperazinepyridyl derivatives on release and inhibition of reuptake of dopamine, serotonin and noradrenaline by rat brain in vitro". European Journal of Pharmacology. 282 (1–3): 131–135. doi:10.1016/0014-2999(95)00300-A. PMID 7498267.